{"id":1247,"date":"2022-02-07T11:19:08","date_gmt":"2022-02-07T02:19:08","guid":{"rendered":"https:\/\/idsc-gunma.jp\/congress\/jstm\/?p=1247"},"modified":"2022-02-07T11:21:53","modified_gmt":"2022-02-07T02:21:53","slug":"%e3%83%8f%e3%82%a4%e3%83%91%e3%83%bc%e3%82%b5%e3%83%bc%e3%83%9f%e3%82%a2%e3%81%8c%e3%82%93%e6%b2%bb%e7%99%82%e3%81%b8%e3%81%ae%e7%9b%b8%e4%b9%97%e5%8a%b9%e6%9e%9c%e2%80%95%e3%83%97%e3%83%a9%e3%82%ba","status":"publish","type":"post","link":"https:\/\/idsc-gunma.jp\/congress\/jstm\/%e3%83%8f%e3%82%a4%e3%83%91%e3%83%bc%e3%82%b5%e3%83%bc%e3%83%9f%e3%82%a2%e3%81%8c%e3%82%93%e6%b2%bb%e7%99%82%e3%81%b8%e3%81%ae%e7%9b%b8%e4%b9%97%e5%8a%b9%e6%9e%9c%e2%80%95%e3%83%97%e3%83%a9%e3%82%ba\/","title":{"rendered":"\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u304c\u3093\u6cbb\u7642\u3078\u306e\u76f8\u4e57\u52b9\u679c\u2015\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u9162\u9178\u30ea\u30f3\u30b2\u30eb\u6db2\u3068\u306e\u4f75\u7528"},"content":{"rendered":"\n<p>\u4e00\u793e\uff09\u65e5\u672c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u5b66\u4f1a\u30cb\u30e5\u30fc\u30b9\u3010\u5b66\u8853\u5831\u544a70\u3011<\/p>\n\n\n\n<p>\u6700\u8fd1\u306e\u8a71\u984c70\uff082022\/02\/07\u63b2\u8f09\uff09<\/p>\n\n\n\n<p>\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u304c\u3093\u6cbb\u7642\u3078\u306e\u76f8\u4e57\u52b9\u679c\u2015\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u9162\u9178\u30ea\u30f3\u30b2\u30eb\u6db2\u3068\u306e\u4f75\u7528<\/p>\n\n\n\n<p>\u7530\u4e2d \u5b8f\u660c*, \u5800 \u52dd<\/p>\n\n\n\n<p>\u540d\u53e4\u5c4b\u5927\u5b66\u4f4e\u6e29\u30d7\u30e9\u30ba\u30de\u79d1\u5b66\u7814\u7a76\u30bb\u30f3\u30bf\u30fc<\/p>\n\n\n\n<p>\u3000\u8fd1\u5e74\uff0c\u4f4e\u6e29\u30d7\u30e9\u30ba\u30de<sup>\u20201<\/sup>\u306b\u3088\u308b\u304c\u3093\u6cbb\u7642\u7814\u7a76\u304c\u76db\u3093\u306b\u884c\u308f\u308c\u308b\u3088\u3046\u306b\u306a\u308a\uff0c\u305d\u306e\u4e2d\u3067\u3082\u30d7\u30e9\u30ba\u30de\u3092\u7167\u5c04\u3057\u305f\u6eb6\u6db2 (\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u6eb6\u6db2<sup>\u20202<\/sup>\u3068\u547c\u3070\u308c\u308b)\u306b\u3088\u308b\u6297\u816b\u760d\u52b9\u679c\u304c\u6ce8\u76ee\u3092\u96c6\u3081\u3066\u3044\u308b<sup>1)<\/sup>\uff0e2012\u5e74\u306b\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u57f9\u990a\u6db2 (Plasma-Activated Medium, PAM)\u3068\u79f0\u3055\u308c\u308b\u30d7\u30e9\u30ba\u30de\u7167\u5c04\u3057\u305f\u7d30\u80de\u57f9\u990a\u6db2\u304c\u30a2\u30b9\u30c8\u30ed\u30b5\u30a4\u30c8\u306e\u6b63\u5e38\u7d30\u80de\u306b\u5bfe\u3057\u3066\u306f\u5f71\u97ff\u3057\u306a\u3044\u304c\uff0c\u8133\u816b\u760d\u57f9\u990a\u7d30\u80de\u306b\u5bfe\u3057\u3066\u9078\u629e\u7684\u306b\u7d30\u80de\u6bd2\u6027\u3092\u793a\u3059\u304c\u5831\u544a\u3055\u308c\u3066\u4ee5\u6765\uff0c\u69d8\u3005\u306a\u6eb6\u6db2\u3084\u69d8\u3005\u306a\u304c\u3093\u7d30\u80de\u306b\u5bfe\u3057\u3066\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u6eb6\u6db2\u306e\u6297\u816b\u760d\u52b9\u679c\u304c\u5831\u544a\u3055\u308c\u3066\u304d\u305f<sup>2)<\/sup>\uff0e2016\u5e74\u306b\u306f\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u4e73\u9178\u30ea\u30f3\u30b2\u30eb\u6db2\u3084\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u9162\u9178\u30ea\u30f3\u30b2\u30eb\u6db2\u306b\u3088\u308b\u6297\u816b\u760d\u52b9\u679c\u304c\u5831\u544a\u3055\u308c<sup>3)<\/sup>\uff0c\u305d\u308c\u3089\u306e\u6eb6\u6db2\u5185\u306e\u6210\u5206\uff0c\u4f5c\u7528\u6a5f\u5e8f\uff0c\u52d5\u7269\u5b9f\u9a13\u306a\u3069\uff0c\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u6eb6\u6db2\u306e\u81e8\u5e8a\u5fdc\u7528\u306b\u5411\u3051\u305f\u7814\u7a76\u304c\u5e83\u304f\u9032\u3081\u3089\u308c\u3066\u3044\u308b\uff0e<\/p>\n\n\n\n<p>\u3000\u3053\u3053\u3067\u306f\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306b\u52a0\u3048\u3066\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u9162\u9178\u30ea\u30f3\u30b2\u30eb\u6db2 (Plasma-activated Ringer\u2019s acetated solution, PAA)\u3092\u4f75\u7528\u3057\uff0c\u76f8\u4e57\u7684\u306b\u6297\u816b\u760d\u52b9\u679c\u3092\u9ad8\u3081\u308b\u3053\u3068\u3092\u8a3c\u660e\u3057\u305f\u7814\u7a76\u5185\u5bb9\u306b\u3064\u3044\u3066\u7d39\u4ecb\u3059\u308b<sup>4)<\/sup>\uff0eA549\u30d2\u30c8\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7d30\u80de\u682a\u3092\u7528\u3044\u3066\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2 (42<sup>o<\/sup>C)\u53ca\u3073PAA\u306e\u76f8\u4e57\u52b9\u679c\u304c\u8abf\u3079\u3089\u308c\u305f\uff0e\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u5358\u72ec\u3084PAA\u5358\u72ec\u306b\u6bd4\u3079\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068PAA\u306e\u4f75\u7528\u306f\u76f8\u4e57\u7684\u306bA549\u7d30\u80de\u306b\u5bfe\u3057\u3066\u7d30\u80de\u6bd2\u6027\u3092\u793a\u3059\u3053\u3068\u304c\u793a\u3055\u308c\u305f\uff0e\u66f4\u306b\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068PAA\u306e\u4f75\u7528\u306b\u3088\u308aA549\u7d30\u80de\u306e\u7d30\u80de\u5185Ca<sup>2+<\/sup>\u306e\u5897\u52a0\u304c\u78ba\u8a8d\u3055\u308c\u305f\u305f\u3081\uff0cTransient Receptor potential (TRP)\u30c1\u30e3\u30cd\u30eb\u306e1\u7a2e\u3067\u3042\u308bTRPM2 (TRP metastatin 2)<sup>\u20203<\/sup>\u306e\u6a5f\u80fd\u304c\u8abf\u3079\u3089\u308c\u305f\uff0eTRPM2\u306e\u963b\u5bb3\u5264\uff082-aminoethoxydiphenyl borate, 2APB\uff09\u3084<em>siTRPM2<\/em>\u306b\u3088\u308b\u907a\u4f1d\u5b50\u306e\u30ce\u30c3\u30af\u30c0\u30a6\u30f3\u306b\u3088\u308a\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068PAA\u306b\u3088\u308b\u7d30\u80de\u5185Ca<sup>2+<\/sup>\u306e\u5897\u52a0\u3068\u6297\u816b\u760d\u52b9\u679c\u304c\u6291\u5236\u3055\u308c\u305f\u3053\u3068\u304b\u3089\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068PAA\u306e\u4f75\u7528\u306b\u3088\u308b\u6297\u816b\u760d\u52b9\u679c\u306b\u306fTRPM2\u304c\u95a2\u4e0e\u3057\u3066\u3044\u308b\u3053\u3068\u304c\u8a3c\u660e\u3055\u308c\u305f\uff0e\u3055\u3089\u306b\uff0cA549\u7d30\u80de\u306b\u304a\u3051\u308b\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068PAA\u306e\u4f75\u7528\u306b\u3088\u308a\uff0c\u7d30\u80de\u5185\u6d3b\u6027\u9178\u7d20\u7a2e\u306e\u5897\u52a0\uff0cDNA\u306e\u65ad\u7247\u5316, poly(ADP-ribose)polymerase-1(PARP-1)\u306e\u6d3b\u6027\u5316\u306e\u4fc3\u9032, \u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u306e\u8a98\u5c0e\u304c\u793a\u3055\u308c\u305f\uff0e\u4ee5\u4e0a\u3088\u308a\uff0cPAA\u51e6\u7406\u3068\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306e\u4f75\u7528\u306b\u3088\u308a\u7d30\u80de\u5185\u6d3b\u6027\u9178\u7d20\u7a2e\u304c\u5897\u5927\u3057, \u305d\u306e\u7d50\u679cDNA\u306e\u65ad\u7247\u5316\u3068PARP-1\u306e\u6d3b\u6027\u5316\u304c\u4fc3\u9032\u3055\u308c\u308b\uff0e\u305d\u306e\u3053\u3068\u306b\u3088\u3063\u3066TRPM2\u304c\u6d3b\u6027\u5316\u3055\u308c\u3066, \u7d30\u80de\u5185Ca2+\u304c\u3055\u3089\u306b\u5897\u52a0\u3059\u308b\u3053\u3068\u3067\u7d30\u80de\u6b7b\u304c\u8a98\u5c0e\u3055\u308c\u308b\u3068\u3044\u3046\u30e1\u30ab\u30cb\u30ba\u30e0\u304c\u63d0\u5531\u3055\u308c\u305f\uff0e\u3064\u307e\u308a\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306f\u3001\u304c\u3093\u7d30\u80de\u306ePAA\u306b\u5bfe\u3059\u308b\u611f\u53d7\u6027\u3092\u76f8\u4e57\u7684\u306b\u5897\u5f37\u3059\u308b\uff0e\u6b63\u5e38\u7d30\u80de\u3068\u3057\u3066\u7528\u3044\u3089\u308c\u305f\u7dda\u7dad\u82bd\u7d30\u80de\u306b\u304a\u3044\u3066\u306f\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068PAA\u306e\u4f75\u7528\u306b\u3088\u308b\u7d30\u80de\u6bd2\u6027\u306f\u8a8d\u3081\u3089\u308c\u306a\u304b\u3063\u305f\uff0e<\/p>\n\n\n\n<p>\u3000\u6700\u8fd1, \u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068\u4f4e\u6e29\u30d7\u30e9\u30ba\u30de\u306e\u4f75\u7528\u306b\u3088\u308b\u6297\u816b\u760d\u52b9\u679c\u306e\u5897\u5927\u304cU937\u30ea\u30f3\u30d1\u816b\u7d30\u80de\u682a\u3067\u5831\u544a\u3055\u308c\u3066\u304a\u308a<sup>5)<\/sup>\uff0c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3068\u4f4e\u6e29\u30d7\u30e9\u30ba\u30de\/\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u6eb6\u6db2\u3068\u306e\u4f75\u7528\u7642\u6cd5\u306f\uff0c\u6709\u671b\u306a\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u671f\u5f85\u3055\u308c\u308b\uff0e<\/p>\n\n\n\n<p>\u53c2\u8003\u6587\u732e<\/p>\n\n\n\n<p>1. Tanaka H., Bekeschus S., Yan D., Hori M., Keidar M., Laroussi M<em>.<\/em>: Plasma-treated solutions (PTS) in cancer therapy. Cancers, 13: 1737, 2021.<\/p>\n\n\n\n<p>2. Tanaka H., Mizuno, M., Ishikawa, K., Nakamura, K., Kajiyama, H., Kano, H., Kikkawa, F. Hori, M.: Plasma-activated medium selectively kills glioblastoma brain tumor cells by down-regulating a survival signaling molecule, AKT kinase. Plasma Med, 1: 265-277, 2013.<\/p>\n\n\n\n<p>3. Tanaka H., Nakamura K., Mizuno M., Ishikawa K., Takeda K., Kajiyama H., Utsumi F., Kikkawa F., Hori M.: Non-thermal atmospheric pressure plasma activates lactate in Ringer&#8217;s solution for anti-tumor effects. Sci Rep, 6: 36282, 2016.<\/p>\n\n\n\n<p>4. Ishii R., Kamiya T., Hara H., Adachi T.: Hyperthermia synergistically enhances cancer cell death by plasma-activated acetated Ringer&#8217;s solution. Arch Biochem Biophys, 693: 108565, 2020.<\/p>\n\n\n\n<p>5. Moniruzzaman R., Rehman M.U., Zhao Q.L., Jawaid P., Takeda K., Ishikawa K., Hori M., Tomihara K., Noguchi K., Kondo T., Noguchi M.: Cold atmospheric helium plasma causes synergistic enhancement in cell death with hyperthermia and an additive enhancement with radiation. Sci Rep, 7: 11659, 2017.<\/p>\n\n\n\n<p>6. Toyokuni S., Ikehara Y., Kikkawa F., and Hori M., Plasma Medical Science: Academic Press, 1-458, 2018<\/p>\n\n\n\n<p>\u7528\u8a9e\u89e3\u8aac<\/p>\n\n\n\n<p><sup>\u20201<\/sup>\u4f4e\u6e29\u30d7\u30e9\u30ba\u30de\uff1a\u30d7\u30e9\u30ba\u30de\u3068\u306f\uff0c\u56fa\u4f53\uff0c\u6db2\u4f53\uff0c\u6c17\u4f53\u306b\u6b21\u3050\u7b2c4\u306e\u7269\u8cea\u306e\u72b6\u614b\u3092\u6307\u3057\uff0c\u5b87\u5b99\u306e99%\u4ee5\u4e0a\u306f\u30d7\u30e9\u30ba\u30de\u304b\u3089\u69cb\u6210\u3055\u308c\u3066\u3044\u308b\uff0e\u30d7\u30e9\u30ba\u30de\u3092\u7528\u3044\u3066\u5fae\u7d30\u52a0\u5de5\u306a\u3069\u306e\u30e2\u30ce\u3065\u304f\u308a\u306f\u5168\u7523\u696d\u306e\u57fa\u5e79\u6280\u8853\u3068\u306a\u3063\u3066\u3044\u308b\uff0e\u6700\u8fd1\uff0c\u771f\u7a7a\u4e0b\u3067\u306a\u304f\u5927\u6c17\u5727\u4e0b\u3067\u751f\u4f53\u306b\u71b1\u306e\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u3053\u3068\u306a\u304f\u30d7\u30e9\u30ba\u30de\u3092\u7167\u5c04\u3059\u308b\u6280\u8853\u306e\u9032\u6b69\u306b\u3088\u308a\uff0c\u4f4e\u6e29\u5927\u6c17\u5727\u30d7\u30e9\u30ba\u30de (CAP: cold atmospheric plasma\u3068\u79f0\u3055\u308c\u308b)\u3092\u533b\u7642\u5fdc\u7528\u3084\u8fb2\u696d\u5fdc\u7528\u3059\u308b\u8a66\u307f\u304c\u76db\u3093\u306b\u884c\u308f\u308c\u308b\u3088\u3046\u306b\u306a\u3063\u305f\uff0e\u6211\u304c\u56fd\u3067\u306f\uff0c2012\u5e74\u5ea6\uff5e2016\u5e74\u5ea6\u306b\u65b0\u5b66\u8853\u9818\u57df\u300c\u30d7\u30e9\u30ba\u30de\u533b\u7642\u79d1\u5b66\u306e\u5275\u6210\u300d(\u9818\u57df\u4ee3\u8868\uff1a\u5800 \u52dd)\u304c\u7acb\u3061\u4e0a\u304c\u308a\uff0c\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u6eb6\u6db2\u306e\u751f\u7269\u52b9\u679c\u3092\u542b\u3081\u672c\u5206\u91ce\u306b\u304a\u3044\u3066\u4e16\u754c\u3092\u727d\u5f15\u3059\u308b\u6210\u679c\u304c\u6319\u3052\u3089\u308c\u3066\u304d\u305f\uff0e\u300cPlasma Medical Science\u300d<sup>6)<\/sup>\u306f\u3053\u306e\u5206\u91ce\u3092\u7d39\u4ecb\u3057\u305f\u53e2\u66f8\u3067\u3042\u308b\uff0e<\/p>\n\n\n\n<p><sup>\u20202<\/sup>\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u6eb6\u6db2\uff1a\u30d7\u30e9\u30ba\u30de\u3092\u7167\u5c04\u3057\u305f\u6eb6\u6db2\u306e\u3053\u3068\u3067\u57f9\u990a\u6db2\uff0c\u70b9\u6ef4\u306a\u3069\u3092\u30d7\u30e9\u30ba\u30de\u7167\u5c04\u3059\u308b\u3068 (\u305d\u308c\u305e\u308c\u300c\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u57f9\u990a\u6db2\u300d\uff0c\u300c\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u70b9\u6ef4\u300d\u3068\u547c\u3076)\u6297\u816b\u760d\u52b9\u679c\u306a\u3069\uff0c\u7d30\u80de\u30fb\u7d44\u7e54\u306b\u591a\u69d8\u306a\u751f\u7406\u5b66\u7684\u5fdc\u7b54\u3092\u793a\u3059\u3053\u3068\u304c\u3053\u308c\u307e\u3067\u306e\u7814\u7a76\u3067\u5206\u304b\u3063\u3066\u304d\u305f\uff0e<\/p>\n\n\n\n<p><sup>\u20203<\/sup>TRPM2: Transient receptor potential melastatin 2\uff0eCa<sup>2+<\/sup>\u900f\u904e\u6027\u3092\u6301\u3063\u305f\u975e\u9078\u629e\u7684\u967d\u30a4\u30aa\u30f3\u30c1\u30e3\u30cd\u30eb\u3067\uff0c\u904e\u9178\u5316\u6c34\u7d20\u306a\u3069\u306b\u3088\u308b\u9178\u5316\u30b9\u30c8\u30ec\u30b9\u306b\u3088\u308a\u6d3b\u6027\u5316\u3055\u308c\u308b\uff0eTRPM2\u30c1\u30e3\u30cd\u30eb\u306e\u6d3b\u6027\u5316\u958b\u53e3\u306b\u3088\u308a\uff0e\u819c\u96fb\u4f4d\u306e\u5909\u5316\uff0cCa<sup>2+<\/sup>\u306e\u7d30\u80de\u5185\u6d41\u5165\u306b\u3088\u308b\u69d8\u3005\u306a\u7d30\u80de\u5fdc\u7b54\u304c\u5f15\u304d\u8d77\u3053\u3055\u308c\u308b\uff0e<\/p>\n\n\n\n<p>\u5229\u76ca\u76f8\u53cd\u306b\u95a2\u3059\u308b\u958b\u793a<br>\u3000\u8457\u8005\u306b\u5229\u76ca\u76f8\u53cd\u72b6\u614b\u306f\u8a8d\u3081\u3089\u308c\u306a\u304b\u3063\u305f\uff0e<\/p>\n\n\n\n<p>Mini-review<\/p>\n\n\n\n<p>Synergistic Effects on Hyperthermic Cancer Therapy Using Plasma-activated Acetated Ringer&#8217;s Solution<\/p>\n\n\n\n<p>Hiromasa Tanaka<sup>*<\/sup>, Masaru Hori<\/p>\n\n\n\n<p>Center for Low-temperature Plasma Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan<\/p>\n\n\n\n<p><sup>*<\/sup>Corresponding author: <a href=\"mailto:htanaka@plasma.engg.nagoya-u.ac.jp\">htanaka@plasma.engg.nagoya-u.ac.jp<\/a><\/p>\n\n\n\n<p>Key Words: low-temperature plasma, plasma activated solutions, plasma activated Ringer\u2019s acetated solution, hyperthermia<\/p>\n\n\n\n<p>Received: 19 July, 2021<\/p>\n\n\n\n<p>Accepted: 30 July, 2021<\/p>\n\n\n\n<p>Vol.37 (4)\u63b2\u8f09\u6e08\u307f<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e00\u793e\uff09\u65e5\u672c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u5b66\u4f1a\u30cb\u30e5\u30fc\u30b9\u3010\u5b66\u8853\u5831\u544a70\u3011 \u6700\u8fd1\u306e\u8a71\u984c70\uff082022\/02\/07\u63b2\u8f09\uff09 \u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u304c\u3093\u6cbb\u7642\u3078\u306e\u76f8\u4e57\u52b9\u679c\u2015\u30d7\u30e9\u30ba\u30de\u6d3b\u6027\u9162\u9178\u30ea\u30f3\u30b2\u30eb\u6db2\u3068\u306e\u4f75\u7528 \u7530\u4e2d \u5b8f\u660c*, \u5800 \u52dd \u540d\u53e4\u5c4b\u5927\u5b66\u4f4e\u6e29\u30d7\u30e9\u30ba\u30de [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"vkexunit_cta_each_option":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-1247","post","type-post","status-publish","format-standard","hentry","category-report"],"_links":{"self":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/1247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/comments?post=1247"}],"version-history":[{"count":1,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/1247\/revisions"}],"predecessor-version":[{"id":1248,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/1247\/revisions\/1248"}],"wp:attachment":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/media?parent=1247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/categories?post=1247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/tags?post=1247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}